Oncotelic Announces Formation of Animal Health Division

AGOURA HILLS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), directly and / or through its wholly owned subsidiaries Oncotelic Inc. and PointR Data Inc., a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced the formation of an animal health division.

One of the objectives being evaluated by the Company within the new initiative is the democratization of the animal health space through application of blockchain technology and a decentralized autonomous organization (DAO) against our current portfolio. We acknowledge that the power of a DAO, as it is being used today and the consistent innovations it brings as time goes on, has the potential to enhance drug development for a largely unmet market for animals, and pets in particular.

“We are really excited to see what the future holds with DAOs and animal health in general and for the Company. While it is only one of the many objectives being contemplated within this new division, we believe that our current portfolio of drug candidates could be successful in the animal health segment” said Dr. Vuong Trieu, Chairman and CEO – Oncotelic.

Oncotelic’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Al statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “wil”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements . Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the development of our product pipeline for animal health products, use of blockchain technology to enhance the drug development process, scope and success of our product development efforts in the animal health space and the potential use of the company’s product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at a l. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment , failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company’s annual report on Form 10-K filed with the SEC on April 15, 2022 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact information:
For Oncotelic Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com

.

Related Articles

The Fine Art of Blowing Up Pipelines in a Post-Truth Era

I've always found conspiracy theories to be fascinating, not just individually, but as a concept in and of itself. I spent the darker...

‘Black Adam’ Post-Credit Scene Videos Leaked From Global Premiere Are Taken Down by Twitter

After Warner Bros.' global premiere of the DC superhero movie “Black Adam” in New York, footage of the film's post-credit scene leaked onto...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

The Fine Art of Blowing Up Pipelines in a Post-Truth Era

I've always found conspiracy theories to be fascinating, not just individually, but as a concept in and of itself. I spent the darker...

‘Black Adam’ Post-Credit Scene Videos Leaked From Global Premiere Are Taken Down by Twitter

After Warner Bros.' global premiere of the DC superhero movie “Black Adam” in New York, footage of the film's post-credit scene leaked onto...

Best comedy podcasts for kids

We've rounded up comedy...

Vegan Dog Food: Vet-Recommended Brands And What Pet Parents Should Know – DodoWell

With vegan and vegetarian diets becoming more and more popular, some pet parents who've made the leap are wondering if their dogs can also...